Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedApr 12, 2026
DataAggregated Company Financials
Companies315
  • 7D-0.6%
  • 3M-0.8%
  • 1Y39.1%
  • YTD0.7%

In the last week, Pharma has been flat. The past year has been better, since the industry has gained 39% in that time. Looking forward, earnings are forecast to grow by 11% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 12 Apr 2026US$2.3tUS$405.9bUS$72.5b17x31.4x5.6x
Tue, 10 Mar 2026US$2.3tUS$406.1bUS$72.5b18.8x31.8x5.7x
Thu, 05 Feb 2026US$2.3tUS$411.5bUS$73.2b21.1x31.4x5.6x
Sat, 03 Jan 2026US$2.2tUS$402.6bUS$71.5b19.9x31.4x5.6x
Mon, 01 Dec 2025US$2.2tUS$402.7bUS$71.4b20.6x31.2x5.5x
Wed, 29 Oct 2025US$1.9tUS$389.2bUS$63.5b17.3x29.8x4.9x
Fri, 26 Sep 2025US$1.8tUS$387.9bUS$60.9b18.2x28.9x4.5x
Sun, 24 Aug 2025US$1.8tUS$387.8bUS$60.9b19.6x29.1x4.6x
Tue, 22 Jul 2025US$1.7tUS$384.0bUS$62.1b17.5x28.1x4.5x
Thu, 19 Jun 2025US$1.8tUS$382.7bUS$61.2b17.6x28.7x4.6x
Sat, 17 May 2025US$1.6tUS$382.6bUS$61.2b17.2x26.8x4.3x
Mon, 14 Apr 2025US$1.6tUS$380.0bUS$40.6b15.5x40.3x4.3x
Wed, 12 Mar 2025US$1.9tUS$381.1bUS$39.2b15.6x48.3x5x
Fri, 07 Feb 2025US$1.9tUS$379.9bUS$40.8b18.7x45.8x4.9x
Sun, 05 Jan 2025US$1.8tUS$369.3bUS$31.3b17x57.3x4.9x
Tue, 03 Dec 2024US$1.9tUS$373.8bUS$30.6b19.5x60.7x5x
Thu, 31 Oct 2024US$2.0tUS$369.5bUS$30.5b18.7x64.8x5.4x
Sat, 28 Sep 2024US$2.0tUS$364.1bUS$25.3b19.1x79.4x5.5x
Mon, 26 Aug 2024US$2.0tUS$362.1bUS$21.8b17.9x93.8x5.6x
Wed, 24 Jul 2024US$2.0tUS$356.5bUS$13.1b16.1x149.6x5.5x
Fri, 21 Jun 2024US$1.9tUS$358.3bUS$14.0b15.6x138.3x5.4x
Sun, 19 May 2024US$1.9tUS$358.3bUS$14.0b18.2x133.8x5.2x
Tue, 16 Apr 2024US$1.8tUS$357.2bUS$23.9b22.8x75.6x5.1x
Thu, 14 Mar 2024US$1.9tUS$355.4bUS$22.3b20.3x84.5x5.3x
Sat, 10 Feb 2024US$1.9tUS$354.9bUS$23.0b31.7x80.6x5.2x
Mon, 08 Jan 2024US$1.8tUS$375.2bUS$33.8b27.5x52x4.7x
Wed, 06 Dec 2023US$1.7tUS$375.1bUS$33.9b27.3x49.1x4.4x
Fri, 03 Nov 2023US$1.6tUS$374.3bUS$35.4b19x45x4.3x
Sun, 01 Oct 2023US$1.6tUS$381.8bUS$43.8b19x37.7x4.3x
Tue, 29 Aug 2023US$1.8tUS$381.6bUS$44.1b20.5x40.2x4.6x
Thu, 27 Jul 2023US$1.7tUS$394.3bUS$60.8b18.7x28.3x4.4x
Sat, 24 Jun 2023US$1.8tUS$392.8bUS$60.1b18.9x29.2x4.5x
Mon, 22 May 2023US$1.7tUS$392.9bUS$60.5b19.1x28.5x4.4x
Wed, 19 Apr 2023US$1.6tUS$402.6bUS$63.3b17.5x26x4.1x
Price to Earnings Ratio

26x


Total Market Cap: US$1.6tTotal Earnings: US$63.3bTotal Revenue: US$402.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 53.7x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 31.4x which is lower than its 3-year average PE of 53.7x.
  • The 3-year average PS ratio of 4.9x is lower than the industry's current PS ratio of 5.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 4.6% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market3.38%
Healthcare0.32%
Pharma-0.60%
Pharma-0.60%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$939.470.4%
+US$3.5b		28.3%PE40.7x
MRK MerckUS$121.420.5%
+US$1.1b		53.3%PE16.4x
TEVA Teva Pharmaceutical IndustriesUS$30.822.5%
+US$861.7m		129.0%PE25.5x
OGN OrganonUS$8.8338.8%
+US$643.0m		-21.0%PE12.3x
AXSM Axsome TherapeuticsUS$178.115.7%
+US$491.3m		81.6%PS14.3x

Latest News

CRNX
US$39.44
Crinetics Pharmaceuticals
7D
5.9%
1Y
35.5%
JNJ
US$238.46
Johnson & Johnson
7D
-1.9%
1Y
57.2%
OGN
US$8.83
Organon
7D
38.8%
1Y
-21.0%
RPRX
US$47.90
Royalty Pharma
7D
-1.4%
1Y
49.9%
ELVN
US$45.32
Enliven Therapeutics
7D
16.7%
1Y
174.5%
TEVA
US$30.82
Teva Pharmaceutical Industries
7D
2.5%
1Y
129.0%

Late Stage Pipeline And Margin Expansion Will Transform This Pharma Into A Future Cash Engine

Catalysts About Teva Pharmaceutical Industries Teva Pharmaceutical Industries develops and sells generic medicines, biosimilars and branded therapies across central nervous system, respiratory and immunology related diseases. What are the underlying business or industry changes driving this perspective?
MRK
US$121.42
Merck
7D
0.5%
1Y
53.3%
ZTS
US$117.86
Zoetis
7D
-0.07%
1Y
-21.1%
LLY
US$939.47
Eli Lilly
7D
0.4%
1Y
28.3%
JAZZ
US$194.20
Jazz Pharmaceuticals
7D
3.9%
1Y
93.2%
AXSM
US$178.11
Axsome Therapeutics
7D
5.7%
1Y
81.6%
BMY
US$58.62
Bristol-Myers Squibb
7D
-1.6%
1Y
15.6%
ESPR
US$2.17
Esperion Therapeutics
7D
-16.9%
1Y
112.7%

ESPR: Vision 2040 And Corstasis Deal Will Likely Expose Execution Risks

Analysts raised their price target on Esperion Therapeutics to $5 from $4, citing the company's Q4 results, continued execution of its Vision 2040 plans, the acquisition of Corstasis Therapeutics, and progress with ESP-2001 as key reasons for the update. Analyst Commentary The latest research update highlights that the higher US$5 price target reflects Q4 results that were in line with January guidance, along with continued execution of the Vision 2040 plans.
PFE
US$26.92
Pfizer
7D
-4.9%
1Y
22.9%

PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating

Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.
RGC
US$28.82
Regencell Bioscience Holdings
7D
-6.4%
1Y
2,918.6%
PHVS
US$26.63
Pharvaris
7D
-6.8%
1Y
121.9%